The AAV2 Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 1 (AAV2) particles in both cell lysates and cell supernatants.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Feature | Specification |
---|---|
Application | Bioprocessing |
Sample Volume | 5 µL |
The AAV2 Capsid kit is designed for the quantitative measurement of Adeno-associated virus serotype 1 (AAV2) particles in both cell lysates and cell supernatants.
For research use only. Not for use in diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption and disposal requirements under European REACH regulations (EC 1907/2006).
Adeno-associated virus (AA) vectors are the leading platform for gene delivery for the treatment of a variety of human diseases. AAV Serotype 2 (AAV2) was one of the first AAV serotypes studied and used as vectors for specific and natural tropism towards targeted cell types such as neurons and hepatocytes or tissues such as skeletal muscles and the retina. The AAV2 kit is designed to detect and quantify AAV2 particles in an easy-to-use, no-wash format. The simple and robust procedure benefits from increased throughput compared to ELISA.
Application |
Bioprocessing
|
---|---|
Brand |
HTRF
|
Detection Modality |
HTRF
|
Lysis Buffer Compatibility |
Lysis Buffer 1
Lysis Buffer 2
Lysis Buffer 3
Lysis Buffer 4
|
Product Group |
Kit
|
Sample Volume |
5 µL
|
Shipping Conditions |
Shipped in Dry Ice
|
Target Class |
Viral Particles
|
Technology |
TR-FRET
|
Unit Size |
10,000 Assay Points
|
The Adeno-Associated Virus serotype 1 (AAV2) assay measures AAV2 Capsid in cell supernatant or cell lysate. The assay uses two anti-AAV2 antibodies: one coupled to HRP, that binds to anti-HRP d2 (acceptor) in premix 1, and the other coupled to biotin, that binds to Streptavidin Eu-cryptate (donor) in premix 2. In presence of AAV2 Capsid in a cell extract or supernatant, the addition of these conjugates brings the donor fluorophore into close proximity with the acceptor, and thereby generates a FRET signal. Its intensity is directly proportional to the concentration of the capsid present in the sample and provides a means of assessing any changes caused by experimental variability under a no-wash assay format.
The AAV2 Capsid assay protocol using a 384-well small volume white plate is described on the right. 5 µL of sample or standard and 5 µL of diluent are dispensed directly into the plate for detection by HTRF® reagents. The Biotin anti-AAV2 antibody is pre-mixed with Streptavidin labeled with the donor, and HRP anti-AAV2 antibody is pre-mixed with anti-HRP labeled with the acceptor. 5 µL of each premix were added. The assay can be run in up to a 1536-well format by simply resizing each addition volume proportionally.
Sample size | 5 µL |
---|---|
Final assay volume | 20 µL |
Time to results | Overnight at RT |
Detection limit (LOD) in diluent | 1.11E+09 VP/mL |
Dynamic Range | 4.35E+09 – 6.00E+11 VP/mL |
Sample compatibility |
From raw harvest material to the final product Supernatant, Cell Lysate (LB#3) |
Intra-assay
Sample |
Mean [AAV2] (VP/mL) |
CV |
---|---|---|
1 |
4.00E+11 |
3% |
2 |
1.00E+10 |
2% |
3 |
2.50E+10 |
2% |
|
Mean CV |
2% |
Each of the 3 samples was measured 24 times, and % CV was calculated for each sample.
Inter-assay
Sample |
Mean [AAV2] (VP/mL) |
CV |
---|---|---|
1 |
4.00E+11 |
1% |
2 |
1.00E+10 |
8% |
3 |
2.50E+10 |
1% |
|
Mean CV |
3% |
Each of the samples was measured in 3 independent experiments performed by different operators, and the % CV was calculated for each sample.
Dilution Factor |
[AAV2] Expected (VP/mL) |
[AAV2] Mesured (VP/mL) |
Dilution Recovery |
---|---|---|---|
Neat |
- |
3.76E+11 |
100% |
2 |
1.88E+11 |
1.82E+11 |
103% |
4 |
9.39E+11 |
8,84E+10 |
106% |
8 |
4.69E+10 |
4.50E+10 |
104% |
16 |
2.35E+10 |
2.71E+10 |
87% |
Mean |
|
|
103% |
[AAV2] (VP/mL) |
[Total Protein] SF9 cell lysates Spiked Sample (mg/mL) |
Recovery |
---|---|---|
1.0E+11 |
0.188 |
54% |
0.094 |
72% |
|
0.047 |
86% |
|
0.023 |
84% |
[AAV2] (VP/mL) |
[Total Protein] HEK293 cell lysates Spiked Sample (mg/mL) |
Recovery |
---|---|---|
1.0E+11 |
1.500 |
72% |
0.750 |
67% |
|
0,375 |
85% |
|
0.188 |
89% |
|
0.094 |
90% |
Sample |
[AAV2] Standard (VP/mL) |
SF9 cell lysate (0.05 mg/ml) |
---|---|---|
Recovery |
||
1 |
8.77E+10 |
86% |
2 |
3.56E+10 |
103% |
3 |
1.04E+10 |
85% |
|
Mean CV |
91% |
Sample |
[AAV2] Standard (VP/mL) |
HEK293 cell lysate (0.4 mg/ml) |
Recovery |
||
1 |
1.00E+11 |
87% |
2 |
2.50E+10 |
83% |
3 |
1.25E+09 |
87% |
|
Mean CV |
86% |
Cross reactivities were assessed using other serotypes from the AAVs family. Standard curves were generated for each serotype using AAVs capsids diluted in the kit diluent.
5 µL of capsids were transferred into a white detection plate (384 low volume), and 5 µL of diluent followed by 10 µL of the HTRF AAV2 capsid detection reagents were added. The HTRF signal was recorded after an overnight incubation at room temperature.
The assay shows differential affinities depending on the serotype, but does not detect AAV8 and AAV9.
To demonstrate the detection of both full and empty AAV2 capsids, recognition of full AAV2-CMV-eGFP and empty AAV2 capsids was analyzed in the assay. A large range of AAV2-CMV-eGFP concentrations (GC/mL) were convert into VP/mL using an independent sample quantitation assay. 5 µL of full or empty capsids diluted in the kit diluent were then transferred into a white detection plate (384 low volume), and 5 µL of diluent followed by 10 µL of the HTRF AAV2 capsid detection reagents were added. The HTRF signal was recorded after an overnight incubation at room temperature. As expected, the HTRF AAV2 capsid detection assay could detect both full and empty AAV2 capsids in the same way.
Are you looking for resources, click on the resource type to explore further.
When a genetic mutation occurs, it can lead to the development of different pathologies. Over the past 10 years exciting...
We are here to answer your questions.